A Phase 3 interventional study of placebo and linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 25 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 2 that started in 2016, is one of 31 in phase 3, and was the 55th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 61st largest by enrollment of the 96 interventional ones that give a count, is one of 6 that started in 2016, is one of 50 in phase 3, and was the 102nd registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Chinese male or female patients who are pre-treated with insulin alone or in combination with metformin:
Women of must be ready and able to use highly effective methods of per ICH (International Conference on Harmonisation) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: linagliptin · Drug: background therapy
Drug: placebo · Drug: background therapy
insulin with or without metformin
Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
Percentage change from baseline, that is, \[\[(HbA1c after 24 weeks of treatment) - (HbA1c at baseline)\] / (HbA1c at baseline)\] \*100%, where baseline refers to the last observation prior to the start of randomised study drug, including the observation prior to the placebo run-in.
Time frame: Baseline and week 24
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
Change from baseline in Fasting plasma glucose (FPG) after 24 weeks of treatment.
Time frame: Baseline and week 24
Change From Baseline in 2-hour (2-h) Postprandial Plasma Glucose (PPG) After 24 Weeks of Treatment
Change from baseline in 2-hour (2-h) postprandial plasma glucose (PPG) after 24 weeks of treatment.
Time frame: Baseline and week 24
Percentage of Participants With HbA1c on Treatment <7.0 Percentage (%) After 24 Weeks of Treatment
Percentage of participants with HbA1c on treatment \<7.0 percentage (%) after 24 weeks of treatment. Participants with baseline HbA1c \<7.0% were excluded from the analysis.
Time frame: 24 weeks
Percentage of Participants With HbA1c on Treatment < 6.5% After 24 Weeks of Treatment
Percentage of participants with HbA1c on treatment \< 6.5% after 24 weeks of treatment. Participants with baseline HbA1c \<6.5% were excluded from the analysis.
Time frame: 24 weeks
Percentage of Participants With HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment
Percentage of participants with HbA1c lowering by at least 0.5% after 24 weeks of treatment.
Time frame: 24 weeks
Percentage of Participants With Any Investigator-defined Hypoglycaemic Adverse Event (AE) With Plasma Glucose (PG) ≤70 mg/dL
Incidence of investigator-reported hypoglycaemic events confirmed by a measured blood glucose ≤70 mg/dL (≤3.9 Millimoles Per Litre (mmol/L)). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Time frame: 24 weeks
Percentage of Participants With Any Severe Hypoglycaemic AE
Incidence of severe hypoglycaemic events (requiring active assistance by another person, or fatal). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Time frame: 24 weeks
This was a randomised, double-blind, multi-centre, and placebo-controlled, parallel group study to compare linagliptin with placebo as add-on therapy to stable insulin alone (basal insulin, premixed insulin) or in combination with metformin in Chinese type 2 diabetes mellitus (T2DM) participants with insufficient glycaemic control.
| Milestone | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Started | 102 | 104 |
| Completed | 97 | 98 |
| Not completed | 5 | 6 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Other than listed above | 0 | 1 |
Percentage change from baseline, that is, \[\[(HbA1c after 24 weeks of treatment) - (HbA1c at baseline)\] / (HbA1c at baseline)\] \*100%, where baseline refers to the last observation prior to the start of randomised study drug, including the observation prior to the placebo run-in.
| Percentage change | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment | -0.20 ± 0.09 | -0.61 ± 0.09 |
Change from baseline in Fasting plasma glucose (FPG) after 24 weeks of treatment.
| Milligram/Decilitre (mg/dL) | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment | 0.7 ± 3.6 | -5.5 ± 3.6 |
Change from baseline in 2-hour (2-h) postprandial plasma glucose (PPG) after 24 weeks of treatment.
| mg/dL | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Change From Baseline in 2-hour (2-h) Postprandial Plasma Glucose (PPG) After 24 Weeks of Treatment | -0.06 ± 5.98 | -32.01 ± 5.66 |
Percentage of participants with HbA1c on treatment \<7.0 percentage (%) after 24 weeks of treatment. Participants with baseline HbA1c \<7.0% were excluded from the analysis.
| Percentage of participants | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage of Participants With HbA1c on Treatment <7.0 Percentage (%) After 24 Weeks of Treatment | 8.2 | 13.9 |
Percentage of participants with HbA1c on treatment \< 6.5% after 24 weeks of treatment. Participants with baseline HbA1c \<6.5% were excluded from the analysis.
| Percentage of participants | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage of Participants With HbA1c on Treatment < 6.5% After 24 Weeks of Treatment | 3.0 | 4.0 |
Percentage of participants with HbA1c lowering by at least 0.5% after 24 weeks of treatment.
| Percentage of participants | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage of Participants With HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment | 36.0 | 55.4 |
Incidence of investigator-reported hypoglycaemic events confirmed by a measured blood glucose ≤70 mg/dL (≤3.9 Millimoles Per Litre (mmol/L)). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
| Percentage of Participants | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage of Participants With Any Investigator-defined Hypoglycaemic Adverse Event (AE) With Plasma Glucose (PG) ≤70 mg/dL | 7.8 | 10.6 |
Incidence of severe hypoglycaemic events (requiring active assistance by another person, or fatal). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
| Percentage of Participants | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| Percentage of Participants With Any Severe Hypoglycaemic AE | 0.0 | 0.0 |
Collected over From first drug administration until 7 days after the last drug administration, up to 176 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching Linagliptin | 1/102 (1%) | 17/102 (16.7%) | 26/102 (25.5%) |
| Linagliptin | 0/104 (0%) | 10/104 (9.6%) | 33/104 (31.7%) |
| Event | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| CataractEye disorders | 2/102 | 1/104 |
| Diabetic neuropathyNervous system disorders | 0/102 | 2/104 |
| Angina pectorisCardiac disorders | 1/102 | 0/104 |
| Coronary artery diseaseCardiac disorders | 1/102 | 0/104 |
| Conductive deafnessEar and labyrinth disorders | 1/102 | 0/104 |
| Deafness neurosensoryEar and labyrinth disorders | 1/102 | 0/104 |
| OphthalmoplegiaEye disorders | 1/102 | 0/104 |
| PterygiumEye disorders | 1/102 | 0/104 |
| Abdominal discomfortGastrointestinal disorders | 1/102 | 0/104 |
| Drug-induced liver injuryHepatobiliary disorders | 1/102 | 0/104 |
| Event | Placebo Matching Linagliptin | Linagliptin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 13/102 | 18/104 |
| Upper respiratory tract infectionInfections and infestations | 13/102 | 14/104 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/102 | 6/104 |
Treated set (TS) : The TS consisted of all patients treated with at least one dose of study drug.
| Age, Continuous(Years) | Placebo Matching Linagliptin | Linagliptin | Total |
|---|---|---|---|
| Mean | 57.1 ± 10.6 | 60.1 ± 9.5 | 58.7 ± 10.2 |
| Sex: Female, Male(Participants) | Placebo Matching Linagliptin | Linagliptin | Total |
|---|---|---|---|
| Female | 48 | 52 | 100 |
| Male | 54 | 52 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching Linagliptin | Linagliptin | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 102 | 104 | 206 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching Linagliptin | Linagliptin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 102 | 104 | 206 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Jan 2019, 27 months.
Results were first posted in Jan 2020, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 27 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin